Revenue Breakdown
Composition ()
No data
Revenue Streams
NovaBay Pharmaceuticals Inc (NBY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Avenova, accounting for 88.5% of total sales, equivalent to $2.12M. Other significant revenue streams include Other products and Other revenue, net. Understanding this composition is critical for investors evaluating how NBY navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, NovaBay Pharmaceuticals Inc maintains a gross margin of 8.06%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -224.38%, while the net margin is -255.85%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively NBY converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, NBY competes directly with industry leaders such as EVMN and KROS. With a market capitalization of $281.27M, it holds a significant position in the sector. When comparing efficiency, NBY's gross margin of 8.06% stands against EVMN's 100.00% and KROS's 100.00%. Such benchmarking helps identify whether NovaBay Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
